$1.56
0.00% today
Nasdaq, Apr 01, 06:47 pm CET
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Fortress Biotech, Inc. Stock price

$1.56
-0.01 0.64% 1M
+0.12 7.96% 6M
-0.47 22.96% YTD
-0.43 21.61% 1Y
-18.84 92.35% 3Y
-26.79 94.50% 5Y
-56.19 97.30% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.05 3.11%
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Key metrics

Market capitalization $43.06m
Enterprise Value $21.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.35
P/S ratio (TTM) P/S ratio 0.69
P/B ratio (TTM) P/B ratio 2.03
Revenue growth (TTM) Revenue growth -22.81%
Revenue (TTM) Revenue $62.50m
EBIT (operating result TTM) EBIT $-103.46m
Free Cash Flow (TTM) Free Cash Flow $-153.25m
Cash position $58.85m
EPS (TTM) EPS $-3.27
P/E forward negative
P/S forward 0.78
EV/Sales forward 0.41
Short interest 16.51%
Show more

Is Fortress Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Fortress Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Fortress Biotech, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Fortress Biotech, Inc. forecast:

Buy
100%

Financial data from Fortress Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
63 63
23% 23%
100%
- Direct Costs 26 26
15% 15%
41%
37 37
27% 27%
59%
- Selling and Administrative Expenses 72 72
20% 20%
115%
- Research and Development Expense 61 61
52% 52%
98%
-96 -96
42% 42%
-154%
- Depreciation and Amortization 7.37 7.37
7% 7%
12%
EBIT (Operating Income) EBIT -103 -103
41% 41%
-166%
Net Profit -49 -49
38% 38%
-78%

In millions USD.

Don't miss a Thing! We will send you all news about Fortress Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fortress Biotech, Inc. Stock News

Neutral
GlobeNewsWire
about 21 hours ago
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FD...
Neutral
GlobeNewsWire
4 days ago
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Neutral
Seeking Alpha
6 days ago
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - CFO Srinivas Sidgiddi - VP, R&D Louis Donati - Director, Market Access Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP ...
More Fortress Biotech, Inc. News

Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The company was founded on June 28, 2006 and is headquartered in New York, NY.

Head office United States
CEO Lindsay Rosenwald
Employees 186
Founded 2006
Website www.fortressbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today